Vaxcyte (PCVX) Non-Current Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Non-Current Assets data on file, last reported at $1.5 billion in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $1.5 billion, down 7.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 7.63% YoY), and the FY2025 annual result was $1.4 billion, down 20.19% from the prior year.
• Non-Current Assets advanced to $1.5 billion in Q1 2026 per PCVX's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $1.7 billion in Q4 2024 and troughed at $42.3 million in Q3 2022.
• A 5-year average of $758.9 million and a median of $574.2 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets surged 570.85% in 2024, then retreated 20.19% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $63.6 million in 2022, then soared by 390.33% to $312.0 million in 2023, then jumped by 452.42% to $1.7 billion in 2024, then dropped by 20.19% to $1.4 billion in 2025, then advanced by 11.59% to $1.5 billion in 2026.
• Business Quant data shows PCVX's Non-Current Assets at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.